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Th17 cells, in addition to their proinflamma-
tory functions, have been recognized as
potent inducers of angiogenesis in autoim-
mune diseases and malignancies. In the
present study, we demonstrate distinct
mechanisms by which IL-17 induces lymph-
angiogenesis. Using the mouse cornea mi-
cropocket and cell culture assays, our data
demonstrate that IL-17 directly promotes
growth of lymphatic vessels by inducing
increased expression of prolymphangio-
genic VEGF-D and proliferation of lymphatic
endothelial cells. However, IL-17–induced
growth of blood vessels is primarily medi-
ated through IL-1 secretion by IL-17–
responsive cells. Furthermore, in vivo block-
ade of IL-17 in a preclinical model of Th17-
dominant autoimmune ocular disease
demonstrates a significant reduction in the
corneal lymphangiogenesis and in the pro-
gression of clinical disease. Taken together,
our findings demonstrate a novel prolymp-
hangiogenic function for Th17/IL-17, indicat-
ing that IL-17 can promote the progression
andamplificationof immunity inpart through
its induction of lymphangiogenesis. (Blood.
2011;118(17):4630-4634)
Introduction
CD4T helper-17 (Th17) cell-secreted IL-17A (also known as IL-17) is
a potent proinflammatory cytokine that plays a critical role in the
pathogenesis of multiple autoimmune diseases,1,2 malignancies,3 and
transplant rejections.4 Although IL-17 is expressed only by Th17 cells,
its receptors are ubiquitously expressed in epithelial cells, endothelial
cells, hematopoietic cells, fibroblasts, and osteoblasts.5 Recently, accu-
mulating evidence has demonstrated that, in addition to its proinflamma-
tory activity, IL-17 is a potent angiogenic factor and induces pathologic
hemangiogenesis (blood vessel growth) in tumors6 and in rheumatoid
arthritis.7 However, the effects of IL-17 on lymphangiogenesis are still
not well understood. In the context of immunity, lymphatics serve as
chief conduits for the migration of antigen-presenting cells from the
peripheral tissues to draining lymphoid tissues where they prime naive
T cells to alloantigens or autoantigens.8,9 Lymphangiogenesis is also
thought to play a critical role in cancer metastases to the lymph
nodes.10,11 Furthermore, it is not clear whether IL-17 alone can directly
induce angiogenesis or whether this is secondary to its capacity to
induce IL-17–responsive cells to express the inflammatory cytokine,
IL-1,12,13 which also possesses potent angiogenic activity.14-16 In the
present study, we attempted to dissect the hemangiogenic and lymphan-
giogenic functions of IL-17 using a cornea model of neovascularization
and in vitro assays in the presence of IL-1 blockade. In addition, we
demonstrated the pathologic relevance of IL-17–induced lymphangio-
genesis in a preclinical model of Th17-dominant autoimmune ocular
surface disease.
Methods
Corneal micropocket assay
The corneal micropocket assay was performed as described previously.17
Briefly, hydron pellets containing 100 ng of murine IL-1, IL-17 (Pepro-
Tech), or BSA were implanted into the cornea of BALB/c mice (n 6/
group). Some of the mice with IL-17 pellet received intraperitoneal
injections of 200 g/day either anti–IL-1 antibodies (eBioscience) or
soluble-VEGFR3-Fc chimera (R&D Systems). All animal studies described
herein were conducted under Schepens Eye Research Institute’s Animal
Care and Use Committee approval.
Preclinical model of autoimmune DED
Dry eye disease (DED) was induced in C57BL6 mice as described
previously.2 Clinical disease was scored by fluorescein staining using the
National Eye Institute grading system.18 After DED induction, mice were
divided into 3 groups at day 5 and received twice-daily topical 3 L/eye of
1% anti–IL-17 or isotype antibodies (R&D Systems) or remained untreated
up to day 12.
Cell culture assays
Primary human corneal epithelial cells (CECs) were isolated by corneal
limbal explant culture method, as described previously.19 Human dermal
primary lymphatic microvascular endothelial cells (LECs) were cultured in
EGM-2MV-BulletKit medium (Lonza). Both cell types express IL-17
receptors (supplemental Figure 1A, available on the Blood Web site; see the
Supplemental Materials link at the top of the online article). Cells were
stimulated with 10 ng/mL of human IL-17, IL-1 (PeproTech), or IL-17
along with neutralizing anti–IL-1 antibodies (10 g/mL; eBioscience) for
24 hours. LEC proliferation was measured using the BrdU proliferation kit
(Millipore). CEC and culture supernatants were analyzed for the expression
of different VEGF species by real-time PCR and ELISA kits (R&D
Systems).
Tube formation assay
A transwell Matrigel assay was set up in a 24-well plate in triplicates. A total
of 2  105 Th17 cells (expressing IL-17, but not VEGFs; supplemental
Figures 1B and 2) were added to the upper wells of the transwell along with
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CD3 antibody (0.5 g/mL; eBioscience) to activate Th17 cells to secrete
IL-17, and 1  105 primary corneal epithelial cells to secrete different
VEGFs in response to IL-17–IL-17 receptor interaction. Primary LECs
(5  104) were added in the lower well on Matrigel (Geltrex; Invitrogen). In
some wells of Th17-LEC coculture, soluble IL-17 receptor-Fc or soluble-
VEGFR3-Fc (R&D Systems) was added in media.
Immunohistochemistry
Corneal mounts were immunostained with FITC-conjugated CD31 (Santa
Cruz Biotechnology) and LYVE-1 (Abcam), and rhodamine-conjugated
secondary antibody to LYVE-1 for epifluorescent microscopy.17 The area
covered by blood (CD31hi/LYVE1) and lymph (CD31low/LYVE1hi) ves-
sels was calculated using ImageJ 1.34s software.17
Real-time PCR
RNA was isolated from cells or corneas using RNeasy kit (QIAGEN), and
reverse transcribed using Superscript-III Kit (Invitrogen). PCR was per-
formed using TaqMan mastermix and preformulated primers for murine and
human VEGF-A, VEGF-C, VEGF-D, and GAPDH (Applied Biosystems).
Results and discussion
The cornea serves as an ideal site for angiogenic studies because of
its accessible location, transparent nature, and blood and lymphatic
vessel-free character. Vessels are restricted only to the limbal area
(periphery of the cornea), which grows toward the central cornea in
response to an angiogenic trigger.17,20 Thus, we used a mouse
corneal micropocket model of neovascularization17 to characterize
hemangiogenic and lymphangiogenic activities of IL-17. Pellets
containing IL-1, IL-17, or IL-17 along with systemic blockade of
IL-1 or VEGFR3 were placed in cornea to induce neovasculariza-
tion. Quantification of CD31 and Lyve-1–stained corneas (Figure
1A-B) showed maximum growth of blood vessels with IL-1
pellet, which was 2-fold higher than that observed with the IL-17
pellet (P  .001). Moreover, IL-17 pellet insertion with concurrent
IL-1 blockade showed a significant 50% reduction (P  .002) in
blood vessels compared with IL-17 pellet alone, suggesting that the
hemangiogenic property of IL-17 is primarily via IL-1 secretion.
Quantification of Lyve-1–stained lymphatics (Figure 1A,C) showed
significantly higher (3-fold) lymphangiogenesis with the IL-17
pellet compared with the IL-1 pellet (P  .002). Moreover, the
IL-17 pellet with IL-1 blockade did not show a significant
reduction in lymphangiogenesis compared with the IL-17 pellet
alone (P  .3), clearly indicating that IL-17 primarily has prolymp-
hangiogenic activity independent of the proangiogenic activity of
IL-1. In addition, IL-17 pellet with concurrent VEGFR3 blockade
showed a significant inhibition in IL-17–induced lymphangiogen-
esis (P  .005), but not hemangiogenesis, suggesting that IL-17
induces lymphangiogenesis via a VEGFR3-dependent pathway.
Furthermore, real-time PCR and ELISA analyses (Figure 1D) of
differently stimulated CECs and culture supernatants showed that
IL-17 induced significant increase in the expression of VEGF-A,
VEGF-C, and VEGF-D (P  .05). In contrast, IL-1 primarily
induced increased expression of VEGF-A and VEGF-C, but not of
VEGF-D. Interestingly, CEC stimulated with IL-17 in the presence
of IL-1–blocking antibody showed a significant decrease in the
expression of VEGF-C and VEGF-A, and an increase in VEGF-D
expression compared with those cells stimulated by IL-17 alone
(P  .05; Figure 1D). These results clearly indicate that IL-17–
induced expression of VEGF-A and VEGF-C was primarily
mediated by IL-1 production. However, increased expression of
VEGF-D by IL-17 (even in the presence of IL-1 blockade)
suggests that IL-17 directly up-regulates the VEGF-D expression.
Whereas IL-1 has an inhibitory effect on VEGF-D expression.
Similar to the VEGF-D expression profile, LECs showed an
increase in proliferation when stimulated with IL-17, but not with
IL-1, which was further enhanced in the presence of IL-1
blockade (P  .05; Figure 1E). However, IL-17–mediated LEC
proliferation was significantly inhibited in the presence of
sVEGFR-3 (P  .05), suggesting that IL-17 mediates LEC prolif-
eration indirectly via the VEGFR-3 pathway. Corroborating our
findings on the suppressive effects of IL-1 on VEGF-D, a
previous report has shown that IL-1 down-regulates VEGF-D
expression in cardiac microvascular endothelial cells via the
involvement of ERK1/2, JNKs, and PKC	/ pathways.21
Next, to establish a direct link between Th17 cells, IL-17, and
lymphangiogenesis, we conducted an ex vivo experiment cocultur-
ing Th17 cells and LECs, and measured LEC tube formation
(Figure 1F). LECs cocultured with Th17 cells showed significantly
higher numbers of tube formations, which were comparable with
positive control. However, LEC tube formation was significantly
inhibited when either IL-17 or VEGFR3 was blocked in the
Th17-LEC cocultures (P  .025). These findings clearly demon-
strate and confirm that Th17-secreted IL-17 induces lymphangio-
genesis via a VEGFD/C–VEGFR3 signaling pathway, corroborat-
ing the data of previous experiments showing increased expression
of VEGF-D by IL-17–responsive cells (Figure 1D).
Lymphangiogenesis plays a critical role in tumor metastasis and
in the inflammatory diseases by facilitating immune cell traffick-
ing.8-11 A recent study on lung cancer showed an association
between intratumoral IL-17–postitive cell frequency and lymphat-
ics density, suggesting that IL-17 may play a role in the metastasis
of lung cancer by promoting lymphangiogenesis.22 In addition, in a
preclinical model of Th17-dominant autoimmune DED,2,23 we
have recently reported the occurrence of corneal lymphangiogen-
esis,24 and significantly elevated homing of MHC IIhiCD11b
antigen-presenting cells to the lymphoid tissues24 where they
induce autoreactive T-cell responses.2 We therefore next tested the
relevance of IL-17–mediated lymphangiogenesis using a mouse
model of autoimmune DED2,23 by investigating whether in vivo
IL-17 blockade could inhibit corneal lymphangiogenesis and
progression of the disease. Our results demonstrate that IL-17
blockade significantly reduced the lymphangiogenesis compared
with untreated and isotype Ab-treated DED corneas (P  .0016;
Figure 2A-B). Similarly, harvested corneas showed significantly
low expression of prolymphangiogenic VEGF-D and VEGF-C in
anti–IL-17 Ab-treated DED corneas compared with untreated and
isotype Ab-treated DED corneas (P  .05; Figure 2C). Moreover,
corneal disease scores showed significant reduction in the progres-
sion of clinical disease in the anti–IL-17 Ab-treated group com-
pared with untreated and isotype Ab-treated DED groups (P .004;
Figure 2D). Taken together, these data suggest that, in addition to
causing corneal damage, Th17 cell-secreted IL-17 may promote the
growth of corneal lymphatic vessels in autoimmune disease.
Although it is generally recognized that innate immunity plays a
crucial role in the induction of lymphangiogenesis,25 our data
indicate a new adaptive immune Th17/IL-17–mediated mechanism
in inducing lymphangiogenesis.
In conclusion, the present study provides compelling novel
evidence that Th17/IL-17 has a prolymphangiogenic function that
can further promote the progression and amplification of immunity,
in part through its induction of lymphangiogenesis. Because Th17
cell dysfunctions and lymphangiogenesis are involved in a diverse
array of immunoinflammatory and malignancy disorders, our
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Figure 1. IL-17 promotes lymphangiogenesis by inducing VEGF-D secretion, and proliferation of and tube formation by LECs. (A) Pellets containing 100 ng of IL-1,
IL-17, or IL-17 along with systemic blockade of IL-1 or VEGFR3, were placed in corneal micropockets (n  6 mice/group) to induce angiogenesis.17 After 7 days, corneas
were evaluated biomicroscopically and then harvested for immunostaining with CD31 (green) and Lyve1 (red). Digital micrographs using epifluorescence microscopy were
captured, and ImageJ 1.34s software was used to quantify the growth of (B) blood (CD31hiLyve1) and (C) lymphatic (CD31loLyve1) vessels. (D) Primary human corneal
epithelial cells were cultured with 10 ng/mL concentration of IL-1, IL-17, and IL-17 with IL-1–blocking antibodies for 24 hours, and expression levels of VEGF-A, VEGF-C,
and VEGF-D mRNA in cells, and protein in culture supernatants, were measured by real-time PCR and ELISA, respectively. (E) Primary human LECs were cultured with
10 ng/mL concentrations of IL-1, IL-17, and IL-17 with blockade of IL-1 or VEGFR-3 for 24 hours, and then proliferation was measured using BrdU incorporation assay. (F) In
a transwell Matrigel assay, in vitro polarized 2  105 Th17 cells (in transwell) were cocultured with 5  104 LECs (on Matrigel) in basal MEM with reduced serum (2% FBS).
Positive controls consisted of LEC cultures on Matrigel in MEM supplemented with growth factors (5% FBS, VEGF, FGF, EGF). Negative controls consisted of LEC cultures on
Matrigel in basal MEM only with reduced serum (2% FBS). In some wells of Th17-LEC coculture, soluble-IL-17receptor-Fc or soluble-VEGFR3-Fc was added in media. After 8-
and 24-hour incubation at 37°C, wells were visualized under bright-field inverted microscope to study the LEC tube formations on Matrigel, and digital micrographs were then
captured for quantitative analysis of tube length. Data are mean 
 SEM values of 3 independent experiments. *P  .05, as determined by Student t test. n.s. indicates not
significant.
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findings of inhibiting lymphangiogenesis by targeting Th17/IL-17
may have broader clinical implications beyond the treatment of
ocular immune diseases alone.
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